|
|
August 2003
Colon/Colorectal Cancer
- SWOG N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU
- SWOG R9811: A Phase III Randomized Study Of 5-Fluorouracil, Cisplatin, and Radiotherapy Vs. 5 Fluorouracil, Mitomycin-C and Radiotherapy in Carcinoma of the Anal Canal
Melanoma
- SMT 9801: A Multicenter Trial of Adjuvant Interferon Alfa-2b for Melanoma Patients With Early Lymph Node Metastasis Detected by Lymphatic Mapping and Sentinel Lymph Node Biopsy
- SWOG E4697: A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with “No Evidence of Disease” after Complete Surgical Resection of “Locally Advanced” and/or Stage
IV Melanoma
- SWOG E1697: Phase III Randomized Study of Four Weeks High Dose IFN-2b in Stage T3-T4 or N1 (microscopic)Melanoma
Breast Cancer
- SWOG N9831: Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Therapy for Women with HER-2 Overexpressing Node Positive Breast Cancer
- ACOSOG Z0011: A Randomized Trial of Axillary Node Dissection in Women with Clinical T1-2 N0 M0 Breast Cancer Who Have a Positive Sentinel Node
- CTSU NSABP-33: A Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3 N0-1 M0 Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy
- NSABP B-34: A Clinical Trial Comparing Adjuvant Clodronate Therapy Versus Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy And/Or Tamoxifen or No Therapy
Gastro-intestinal Cancer
- ACOSOG Z9000: A Phase II Study of Adjuvant STI571 (GleevecTM) Therapy in Patients Following Completely Resected High-risk Primary Gastrointestinal Stromal Tumor (GIST)
- ACOSOG Z9001: A Phase III Randomized Double-blind Study of Adjuvant STI571 (GleevecTM) Versus Placebo in Patients Following The Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Lung Cancer
- S9900: A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB (T2 N0), II (T1-2 N1, T3 N0) and Selected III A (T3 N1) Non-Small Cell Lung Cancer (NSCLC)
- S9925: Lung Cancer Specimen Repository Protocol, Ancillary
- EPP 9633: A Phase III Study of Adjuvant Chemotherapy After Resection for Patients with T2 N0 Stage I Non-Small Cell Carcinoma of the Lung
- S0023: A Phase III Trial of Cisplatin /Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy with ZD1839 or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer
- D0112: A Multi-Center, Randomized Phase III Study of Taxotere and Carboplatin versus Taxotere and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer
- Amgen 20020121: A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes during Chemotherapy with or without NeulastaTM (pegfilgrastim) in Subjects with Advanced NSCLC
Prostate Cancer
- RTOG P-0019: A Phase II Study of External Beam Radiation Therapy Combined with Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate
Endometrial Cancer
- RTOG 99-05: A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients with Endometrial Cancer
MDS
- SWOG-9007: Cytogenetic Studies in Leukemia Patients
- SWOG 9910: Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary
Leukemia
- E2997: Phase III Randomized Trial of Fludarabine and Cyclophosphamide versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia
- Amgen 20020163: A Multicenter, Double-Blind, Randomized Phase II Trial Comparing Pegfilgrastim with Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukemia
Liver Cancer
- ZX101-301: A Phase III Randomized Controlled Study Comparing the Survival Of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQTM to Patients Treated With Doxorubicin
Bone Metastases
- ACRIN 6661: A Phase I/II Study of Percutaneous Radiofrequency Ablation of Bone Metastases Using CT Guidance
Lymphoma
- SWOG 9438: Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With interleukin-2 Versus Observation for Patients With Non-Hodgkin’s Lymphoma, a BMT Study, Phase III
- Amgen 20020134: A Multicenter, Double-Blind, Randomized Phase II Study of Pegfilgrastim Administered on the Same Day or the Next Day of R-CHOP Chemotherapy in Subjects with Non-Hodgkin's Lymphoma
Supportive Care
- Amgen 20020122: A Randomized, Open Label, Multicenter Study of Primary Prophylaxis with NeulastaTM (pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (³ 65 y.o.) with Cancer
- ARK 201: A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose-Titration Study of Imidapril Hydrochloride (EG006) in the Treatment of Cancer Cachexia
- PRO2-27-047: A Randomized, Open-Label Study of Epoetin Alfa (PROCRIT®) Versus Darbepoetin Alfa (ARANESPTM) To Evaluate Hematologic Response Rate in Anemic Cancer Patients Receiving Chemotherapy
Oncology Research Team:
Judy Bosley, RN Clinical Research Nurse
Lynn Crawford, RN Clinical research Nurse
Yana Rachinskaya, MS Clinical Research Program Coordinator
The Alvin & Lois Lapidus Cancer Institute
2401 West Belvedere Avenue
Baltimore, Maryland 21215
Phone: 410-601-6120
Fax: 410-601-4714
Back to Top
|
|